CancerDrs

Lymphoma clinical trials in Virginia

23 actively recruiting lymphoma trials at 10 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Virginia:
  • Ballad Health Cancer Care - Bristol — Bristol, Virginia
  • Ballad Health Cancer Care - Norton — Norton, Virginia
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • Naval Medical Center - Portsmouth — Portsmouth, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Virginia:
  • University of Virginia Cancer Center ( Site 0040) — Charlottesville, Virginia
  • Inova Schar Cancer Institute ( Site 0015) — Fairfax, Virginia
  • Virginia Commonwealth University (VCU) Medical Center ( Site 0030) — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Virginia:
  • Virginia Cancer Institute — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Global Trial in APG2575 for Patients With CLL/SLL

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Sites in Virginia:
  • Ascentage Investigative Site — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Virginia:
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06649812
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Virginia:
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Virginia:
  • Virginia Cancer Specialists, PC ( Site 8003) — Manassas, Virginia
  • VCU Health Adult Outpatient Pavillion ( Site 0138) — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Virginia:
  • Virginia Commonwealth University Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Virginia:
  • Children's Hospital of Richmond at VCU — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete resp…

Sponsor: Providence Health & Services
NCT ID: NCT06175000
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immuno…

Sponsor: Virginia Commonwealth University
NCT ID: NCT06846463
Sites in Virginia:
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…

Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Virginia:
  • Virginia Cancer Specialists, PC — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Virginia:
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicin…

Sponsor: BioNTech SE
NCT ID: NCT05142189
Sites in Virginia:
  • NEXT Virginia — Fairfax, Virginia
View on ClinicalTrials.gov →
Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in Virginia:
  • Virginia Commonwealth University/Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Virginia:
  • Massive Bio SYNERGY-AI site — Charlottesville, Virginia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military H…

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT ID: NCT07652580
Sites in Virginia:
  • Naval Medical Center Portsmouth — Portsmouth, Virginia
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Improving Exercise Capacity With a Tailored Physical Activity Intervention

The purpose of this research is to test whether participating in either a physical activity intervention or a series of educational classes will help to preserve exercise capability, heart function, brain-based activities (like memory), an…

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT05595577
Sites in Virginia:
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10